Revenue recognition

12 Months Ended

Dec. 31, 2025

Revenue from Contract with Customer [Abstract]

Revenue recognition

Revenue recognition

a.     Net revenues

The Company’s net revenues by geographic region, based on the patient’s location are summarized as follows:

	Year ended December 31,
	2025		2024		2023
United States	$	385,632	$	391,801	$	349,743
International markets:
Germany	79,407		65,263		60,210
France	76,189		55,730		11,736
Japan	37,786		32,569		31,668
Other international markets	56,898		42,471		32,757
International markets - Total	250,280		196,033		136,371
Greater China (1)	19,441		17,386		23,224
Total net revenues	$	655,353	$	605,220	$	509,338

(1)    For additional information, see c below.

The company's net revenues by performance period are as follows:

	Year ended December 31,
	2025		2024		2023
Net revenues recognized in the reporting period from performance obligations satisfied in:
Reporting period	$	632,358	$	568,819	$	492,089
Previous periods	22,995		36,401		17,249
Total net revenues	$	655,353	$	605,220	$	509,338

b.     Contract balances

The following table provides information about trade receivables, unbilled receivables and contract liabilities from contracts with customers::

	December 31,
	2025		2024
Trade receivables	$	81,648	$	68,501
Unbilled receivables	$	7,787	$	5,725
Deferred revenues (short-term contract liabilities)	$	(15,948)	$	(14,225)

During the years ended December 31, 2025, 2024 and 2023, the Company recognized $14,225, $16,224 and $18,028, respectively, which were included in the deferred revenues (short-term contract liability) balance at January 1, 2025 , 2024 and 2023.

c.     Zai agreement:

The Company recognizes revenue pursuant to the License Agreement with Zai (see Note 12) in accordance with ASC 606, "Revenue Recognition from Customers." The License Fee was deferred and recognized over the performance period commencing September 10, 2018 ("Zai Performance Period"). The potential development and regulatory milestones will be included in the transaction price when the Company concludes that achievement of the milestones is probable, and that recognition of revenue related to the milestones will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price until such probability is achieved. Revenue from royalty payments are estimated and recognized in accordance with ASC 606. Revenues from sales of product or rendering services are recognized upon shipping the products or rendering the services and satisfying the performance obligation.

During the year ended December 31, 2020, the Company triggered milestone payments of $10,000 in the aggregate, which, along with the License Fee, were deferred and recognized over the remainder of the Zai Performance Period on a straight-line basis. For the three years ended December 31, 2025, no additional milestones were included in the transaction price.